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INTRODUCTION
Pancreatic cancer remains a major cause of cancer-related death worldwide and is associated with a dismal prognosis. 1, 2 Curative-intent surgery offers the only chance of survival from pancreatic cancer. However, less than 20% of patients are eligible for resection at the time of diagnosis due to locally advanced or metastatic disease. 1 To facilitate early diagnosis and thus increase resection rates of pancreatic cancer, knowledge on risk factors is essential.
Acute pancreatitis is a sudden-onset inflammatory disease of the pancreas. 3 Although experimental research suggests that acute pancreatitis can induce pancreatic cancer, 4, 5 findings from epidemiological studies are conflicting. [6] [7] [8] [9] A case-control study of ~2,500
patients with pancreatic cancer within the US Veterans Affairs population, 6 and a British matched cohort study of ~6,000 patients with acute pancreatitis, both observed a positive association between acute pancreatitis and pancreatic cancer. 8 However, both studies only excluded pancreatic cancer cases occurring in the first year following acute pancreatitis, which may not allow sufficient time to eliminate reverse causation or surveillance bias. A USbased case-control study including ~300 patients with pancreatic cancer also found a positive association between acute pancreatitis and pancreatic cancer, 7 but did not include any lagperiod from acute pancreatitis to pancreatic cancer. Furthermore, all three studies failed to report estimates of the association at different follow up times. In contrast, a Swedish cohort study of ~25,000 patients with acute pancreatitis reported no association with pancreatic cancer after more than ten years of follow up. 9 Thus, the association between acute pancreatitis and pancreatic cancer requires clarification.
We therefore conducted a nationwide population-based matched cohort study to examine the risk of pancreatic cancer in patients with acute pancreatitis compared with a matched comparison cohort from the general population.
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METHODS
Setting and data sources
We conducted a nationwide, population-based, matched cohort study from January 1980 through October 2013, using data from the Danish National Patient Registry (DNPR), Civil
Registration System, and Danish Cancer Registry. These registries can be linked on an individual level using the Civil Personal Registration (CPR)-number, which is assigned to every Danish resident at birth or immigration.
The DNPR was established in 1977 and contains information on all inpatient hospitalizations to Danish public hospitals. 10 The Civil Registration System, which was established in 1968, is an administrative registry containing data on variables like birth date, sex, sequential dates of migration, and vital status for every resident in Denmark. 11 The Civil Registration System is updated daily and virtually complete.
The Danish Cancer Registry was established in 1943 and includes information on all cancers diagnosed in Denmark. 12 This registry contains information on date of diagnosis, cancer site, histology, dissemination, and other variables.
Acute pancreatitis cohort
From the DNPR, we identified a cohort of all individuals with an inpatient diagnosis of acute pancreatitis from January 1980 through October 2012 (n=44,589), allowing for at least one year of follow up for all patients. We applied a three-year washout period since the start of the DNPR (1977) (1978) (1979) to reduce the likelihood of including prevalent cases of acute pancreatitis.
For each individual, we defined the date of the first diagnosis of acute pancreatitis as their index date. We did not include outpatient diagnoses of acute pancreatitis (n=680), as these are most likely to represent a post-admission follow-up consultation or miscoding. We excluded patients from the acute pancreatitis cohort if they had a diagnosis of pancreatic cancer (n=119), chronic pancreatitis/other exocrine pancreatic disease (n=2,367), or if they underwent pancreatic resection or transplantation (n=49) prior to the index date. Likewise, patients aged less than 18 years at the index date were also excluded (n=385). In total, 41,669
patients were included in this study. A detailed flowchart of the study population is provided in the supplementary material ( Figure S1 ).
Matched comparison cohort
For each patient in the acute pancreatitis cohort, we used the Civil Registration System to identify a pool of individuals from the general population with the same sex and year of birth, who were alive in Denmark on the patient's index date (i.e. the date of the first acute pancreatitis diagnosis). From this pool of eligible comparison subjects, we randomly selected five individuals, thereby constructing a matched comparison cohort. We sampled with replacement, i.e. individuals could act as comparison subjects to several acute pancreatitis patients, but no individual could be sampled more than once to the same patient. 13 Furthermore, we required that the comparison subjects were free of acute pancreatitis, chronic pancreatitis/other exocrine pancreatic disease, and pancreatic cancer, and that they had not undergone pancreatic resection or transplantation prior to the acute pancreatitis patient's index date. We defined the index date for the comparison subjects as the date of diagnosis of the acute pancreatitis patient to whom they were matched. Individuals in the matched comparison cohort entered the acute pancreatitis cohort if they developed acute pancreatitis during follow up (n=1,165), in which case they were censored from the comparison cohort.
Follow up and pancreatic cancer outcome
In order to investigate the risk of pancreatic cancer, we followed the acute pancreatitis patients and the comparison subjects from their respective index dates until pancreatic cancer as recorded in the Danish Cancer Registry; chronic pancreatitis/other exocrine pancreatic disease, pancreatic resection or transplantation (and for comparison subjects also acute pancreatitis); death; emigration; or 1 November 2013, whichever came first.
Comorbidity and surgical procedures
To assess the impact of comorbidity on the association between acute pancreatitis and pancreatic cancer, we retrieved a full medical history from the DNPR for the entire study population. We used this medical history to identify selected conditions that may modify pancreatic cancer risk (obesity, and alcohol-and smoking-related conditions) and to calculate the Charlson Comorbidity Index (CCI) score. 14 We defined three levels of comorbidity: Low (score 0), moderate (score 1-2), and severe (score ≥ 3) comorbidity. We excluded nonmelanoma skin tumors from the CCI score. In addition, we also excluded selected medical conditions (alcohol-and smoking-related diagnoses) from the CCI score, as these covariates were assessed separately. 
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Statistical analyses
We tabulated descriptive characteristics for the study population. Continuous variables were presented as medians with inter-quartile ranges (IQRs). We divided the follow-up time into three periods depending on the time from index date to termination of follow-up: 0-2 years (short term risk), >2-5 years (intermediate term risk), and >5 years (long term risk). At the start of a new follow-up period, we excluded all comparison subjects matched to an acute pancreatitis patient no longer at risk (i.e. the acute pancreatitis patient had met the outcome or any complication listed above, emigrated, or died).
For each follow-up period, we calculated the incidence rate of pancreatic cancer as the number of pancreatic cancers divided by the total person-time accrued in that period. Using stratified Cox proportional hazards regression models, 15 we computed crude and adjusted hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) as a measure of the incidence rate ratio. We developed a directed acyclic graph (DAG) to identify which confounders to adjust for in the multivariate models ( Figure S2 ). In the multivariate model, we stratified on age, sex, calendar year of acute pancreatitis diagnosis, and adjusted for alcohol-and smoking-related conditions, and the CCI score. The proportional hazards assumptions were assessed using log-log plots. Cumulative incidence functions, treating death as a competing risk, were calculated as a measure of the absolute risk in the acute pancreatitis cohort. Data extraction and construction of the matched comparison cohort was performed by UH using SAS (SAS Institute Inc., Cary, North Carolina, USA). All data cleaning and statistical analyses were performed by JK using Stata 13.1 (StataCorp LP, College Station, Texas, USA).
Sensitivity analyses
We performed several sensitivity analyses to examine the robustness of our results. First, we restricted to individuals with at least one year of follow up. Second, we examined the association after a minimum of 10 years of follow up. In both analyses, we followed the individuals from the respective time point until the end of follow-up. Third, we allowed comparison subjects diagnosed with acute pancreatitis after the index date to contribute person-time in both cohorts, resembling an intention-to-treat (ITT) analysis. 16 Fourth, we recalculated the CCI score after five years of follow up (Table S4 ) to assess if additional comorbidity diagnosed within this period had an impact on our estimates. Fifth, we restricted to patients with recurrent acute pancreatitis, defined as two or more hospitalizations for acute pancreatitis, each at least 90 days from discharge until the next admission. 17 We followed these patients from the date of their second acute pancreatitis admission to avoid immortal time bias 18 and adjusted the follow-up start for their matched comparison subjects to the same date. Sixth, we examined the association between acute pancreatitis and pancreatic cancer beyond five years of follow up according to the acute pancreatitis etiology. As information on acute pancreatitis etiology is not routinely recorded in the DNPR, we used the following proxy measures: 1) alcoholic pancreatitis, if a diagnosis of an alcohol-related disease occurred before, or on the same date as the acute pancreatitis diagnosis; 2) biliary pancreatitis, if a diagnosis of gallstone, cholecystitis, cholangitis, or gallstone-pancreatitis was recorded simultaneously with the acute pancreatitis diagnosis; 3) ERCP-pancreatitis, if an ERCP was conducted less than 5 days before the acute pancreatitis diagnosis; and 4) idiopathic, if the etiology was unknown. Patients eligible in more than one of these groups were prioritized according to the listing above. Seventh, we restricted to individuals without a history of smoking-related disease before the index date to assess the impact of confounding from tobacco smoking. Finally, we restricted our analyses to individuals with no history of
smoking-or alcohol-related disease to assess the impact of residual confounding from exposure to these substances.
Ethical considerations
This study was approved by the Danish Data Protection Agency (J.nr. 
RESULTS
Baseline characteristics
We included 41,669 patients with a first-diagnosis of acute pancreatitis and 208,340
comparison individuals, matched on age and sex (Table 1) 
Pancreatic cancer risk
In total, 937 cancers occurred in the study population (Table S5) 
Sensitivity analyses
The first two sensitivity analysis, restricting to patients with acute pancreatitis followed for more than one and 10 years yielded adjusted HRs of 2.40 (95% CI: 1.99-2.88) and 2.21 (95% CI: 1.56-3.13) respectively. The sensitivity analyses, in which we resembled an ITT analysis and reassessed the burden of comorbidity after five years of follow up did not substantially change our estimates. When restricting to patients with recurrent acute pancreatitis (n=4,654;
11.2% of the acute pancreatitis population), our estimate beyond five years of follow up attenuated slightly (aHR: 1.81; 95% CI: 0.65-5.05), although this was imprecise due to few observations. When stratifying the patients according to the acute pancreatitis etiology, our sensitivity analysis suggested that, compared with the general population, patients with idiopathic pancreatitis have the highest pancreatic cancer risk, followed by patients with biliary pancreatitis. No meaningful interpretation can be made from the group of patients with alcoholic or ERCP-related pancreatitis (Table 3) . Finally, our assessment of the impact of confounding from tobacco smoking and alcohol consumption showed no substantial effect on our estimates (Tables S6 and S7) .
In the present study, patients hospitalized with incident acute pancreatitis had an increased risk of pancreatic cancer compared with the general population. Although the risk was highest in the first two years following acute pancreatitis diagnosis, it remained elevated throughout the follow-up period. After both five and ten years of follow up, pancreatic cancer risk in patients with acute pancreatitis was still double that of their matched comparison subjects.
Our results were robust to various sensitivity analyses, except for some variation between subgroups based on the presumed acute pancreatitis etiology.
Several factors require consideration when interpreting our findings. First, our population-based design using Danish population-based and medical registries ensures long term and virtually complete follow up. Second, data in the nationwide registries used in this study has been prospectively registered for administrative and reimbursement purposes, allowing us to obtain a large study population with a high precision for most of our estimates. However, to address this limitation we adjusted our estimates for selected smoking-and alcohol-related conditions. Our afore-mentioned validation study also suggests that alcoholrelated conditions registered in the DNPR are a useful tool to capture alcohol exposure in patients with acute pancreatitis, whereas smoking-related conditions have lower validity.
Residual confounding by tobacco smoking and, partly, alcohol consumption may thus have led to an overestimation of the association between acute pancreatitis and pancreatic cancer.
However, our sensitivity analyses suggest that residual confounding is unlikely to substantially impact our findings. Third, acute pancreatitis etiology (e.g. alcoholic, biliary, ERCP-related, or idiopathic) is not routinely reported in the DNPR. Therefore, we were only able to assess the impact of etiology based on proxy-measures. Although our estimates indicate a lower risk of pancreatic cancer in patients with alcoholic pancreatitis, we emphasize the uncertainty in these proxy measures. This uncertainty is supported by the disproportionately large number of patients in the idiopathic acute pancreatitis group (51.6%) and the substantial variation in our estimates between men and women in the subgroups.
Furthermore, in some of the subgroups, it was doubtful if the proportional hazards assumption was fulfilled.
Most previous studies investigating the association of acute pancreatitis and pancreatic cancer failed to report risk estimates by follow up time. [6] [7] [8] Such estimates are essential to thoroughly interpret and compare findings from different studies, as pancreatic cancer usually evolves over several years. 27 Thus, a pancreatic cancer observed shortly after the start of follow up is likely present at the time of acute pancreatitis diagnosis; acute pancreatitis is unlikely to be a causal factor. This is reflected in our observed 20-fold increased risk of pancreatic cancer within the first two years after acute pancreatitis diagnosis,
consistent with previous research. 28, 29 As such, failing to provide estimates of association at different follow up times leads to a spuriously strong overall association. A US-based pancreatic cancer case-control study by Duell et al. 7 failed to incorporate such a lag-period after acute pancreatitis diagnosis. They reported an odds ratio of 6.4 but the precision of their estimates was limited (95% CI: 2.7-15.0). Moreover, their effect estimates were similar in magnitude among patients with either acute or chronic pancreatitis. As chronic pancreatitis is more strongly associated with pancreatic cancer than acute pancreatitis, 30 their odds ratio of pancreatic cancer could be expected to differ between acute and chronic pancreatitis patients.
In addition, pancreatitis diagnoses in their study were self-reported, thus recall bias and misclassification of acute and chronic pancreatitis seems likely. The study by Duell et al. may also be prone to selection bias as they conducted their study within a selected geographic area and had a response rate of only 67% among both cases and controls.
Our finding of an approximately two-fold increased risk of pancreatic cancer among patients with pancreatitis concurs with other studies. 6, 8 In a Veterans Affairs-based casecontrol study, Bansal et al. 6 provided an unadjusted odds ratio for pancreatic cancer of 1.76 (95% CI: 1.28-2.41) among patients with acute pancreatitis after excluding cases of pancreatic cancer diagnosed within the first year of acute pancreatitis diagnosis. Likewise, Goldacre et al. 8 reported an effect estimate of 3.0 (95% CI: 2.2-4.0) in a British matched cohort study.
Our results agree with these findings, but extend the current knowledge by reporting the association of acute pancreatitis and pancreatic cancer according to follow-up time.
Our observed elevated pancreatic cancer risk beyond five years of follow up compares to findings from a Swedish cohort study by Karlson et al. 9 They report an age-, sex-, and calendar year-standardized incidence ratio (SIR) of pancreatic cancer of 1.6 (95% CI: 1.1-2.2)
in the period five to nine years following acute pancreatitis diagnosis but an attenuated SIR beyond ten years of follow up (SIR: 1.2; 95% CI: 0.7-1.7). In contrast to our study, they In conclusion, patients admitted with acute pancreatitis had an increased risk of pancreatic cancer compared with age-and sex-matched comparison subjects from the general population. Author names in bold designate shared co-first authorships. 
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Other chronic obstructive pulmonary disease -J44 Bronchiectasia 518 J47
Lung cancer 162 C34
All sublevels of a given ICD code are included. M A N U S C R I P T M A N U S C R I P T
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